A new approach to risk stratifying non-alcoholic fatty liver disease (NAFLD) patients in primary care is detailed in an update to one of the Calgary Zone’s most popular pathways.
The revised NAFLD pathway is built around a “paradigm shift” in FIB-4 testing.